Company news
China Medical System Holdings Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Voluntary and Business Update Announcement New Drug Application of Ruxolitinib Phosphate Cream Approved in Singapore
November 3, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 2, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
September 30, 2026
Change of company name of Singapore share transfer agent
September 30, 2026
Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Systemic Lupus Erythematosus of Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001
September 14, 2026
CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China
September 9, 2026
CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
September 3, 2026
CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
June 8, 2026
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
April 27, 2026
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
August 19, 2025